

Fig. S1. *Dll4* overexpression decreases tip cell density in retina vasculature. (A,B) Confocal images of wild-type and *Dll4* gain-of-function retinas at postnatal day P5. Vascular plexus was stained for endothelial marker isolectin B4. *Dll4* overexpression significantly decreases the number of tip cells and filopodia extensions compared with control. Scale bar: 45 μm .




Fig. S2. Quantification of MCA branching in mouse embryos. (A,B) Epifluorescent images of wild-type and *Dll4*^{+/-} brains stained for collagen IV at embryonic stage E14.5. Red dots highlight MCA branch points. Scale bar: 500 μm .





Fig. S3. Genetic and pharmacological inhibition of *Notch1* increases collateral numbers in the brain. (A,B) Inducible endothelium-specific inactivation of *Notch1* was obtained injecting tamoxifen into *Cdh5-CreERT2/R26R/Notch1^{flxed/flxed}* mice at embryonic day E11.5. The E13.5 vascular plexus was stained for collagen IV and β -galactosidase (B, black). Even at low recombination frequency (B), MCA in *Notch1* loss-of-function brains shows hyperbranching, resembling *Dll4^{+/-}* phenotype. Scale bar: 500 μ m. (C) Bar graphs display collateral arteriolar density in P5 and P9 brains after treatment with Notch inhibitor DAPT (100 mg/kg body weight) or vehicle (corn oil) at day P2 and P4. Post-natal DAPT treatment increased pial collateral numbers. Data are shown as mean \pm s.e.m., $n=5$ mice per group. ** $P<0.01$ versus vehicle; *** $P<0.005$ versus vehicle.



A**B**

Fig. S4. Transient inhibition of notch signaling with DAPT augments collateral number without improving stroke volume upon MCA occlusion. (A) Pregnant mice were injected intraperitoneally at E10.5, E11.5 and E12.5 with vehicle (5% ethanol in corn oil) or DAPT at a final concentration of 100 mg/kg. Mice were sacrificed at 8 weeks of age and pial collaterals were counted after PECAM1 staining. There is a significant increase in collateral number in the DAPT-treated group. $*P < 0.05$. Mann-Whitney-U test. (B) Pregnant mice were injected as in A with vehicle or DAPT, and 8-week-old mice were subjected to MCA occlusion and infarct volume was measured. There were no significant differences in infarct volume between the treatment groups.




Fig. S5. Micro-CT analysis of unligated control hindlimb vasculature. (A,B) Quantitative analysis of micro-CT images in thigh and calf of unligated left hindlimb in wild type ($n=4$) and *Dll4*^{+/-} ($n=3$). Shown are total numbers of vascular structures per indicated diameter class in consecutive z -axis slices. (C) Total arteriolar number in unligated left thigh and calf of wild-type and *Dll4*^{+/-} mice based on micro-CT imaging. Vessel numbers are comparable in *Dll4*^{+/-} and wild type. The data are shown as mean \pm s.e.m.




Fig. S6. Arterial blood pressure and heart rate. Mean arterial pressure (MAP in mmHg) (A) and heart rate (HR in beats per minute) (B) in wild-type and *Dll4*^{+/-} mice. The data are shown as mean±s.e.m; wild type, *n*=5; *Dll4*^{+/-}, *n*=6; ***P*<0.01.




Fig. S7. *Dll4* expression in the mouse hindlimb. (A,B) Taqman analysis of *Dll4* expression in the femoral artery (FA) (A) and gastrocnemius muscle (Gastro) (B) of wild-type (*n*=8) and *Dll4*^{+/-} (*n*=8) mice. The data are shown as mean±s.e.m.; **P*<0.05. (C) β -galactosidase staining (*lacZ*) staining on hindlimb cryosections in *Dll4*^{+/-} mice. There is strong staining in vessels.

Table S1. Real-time PCR primers and probes

Gene	Forward primer	Reverse primer	Probe
<i>Hif1a</i>	TCAGAGGAAGCGAAAAATGGA	AGTCACCTGGTTGCTGCAATAA	FAM-5'- TTCCAATTCCTGCTGCTTGAAAAAGGG-3'- TAMRA
<i>Hif1b</i>	GCATGGGCTCACGAAGGT	AACAGGGTCCACGGAGCTAGT	FAM-5'-TTCATCTGCCGCATGAGGTGTGG-3'- TAMRA
<i>Vegfa</i>	GCAGGCTGCTGTAACGATGAA	TTTGATCCGCATGATCTGCAT	FAM-5'-CCCTGGAGTGCGTGCCCA-3'-TAMRA
<i>Kdr</i>	ACTGCAGTGATTGCCATGTTCT	CCTTCATTGGCCCGCTTAA	FAM-5'- TGGCTCCTTCTTGTCATTGTCCTACGGA-3'- TAMRA
<i>Notch1</i>	CATCCGTGGCTCCATTGTCTA	GACGCAAGAGCACCTAGGAA	FAM-5'-TGGAGATCGACAACCGGCAATGT-3'- TAMRA
<i>Dll4</i>	CGAATGCCCCCCTCAACT	GTTTCGGCTTGGACCTCTGTTC	FAM-5'- CGGCTCTAACTGTGAGAAGAAAGTAGACAGG- 3'-TAMRA
<i>Efnb2</i>	TCCAGAGCTAGAAGCTGGTACAAATG	ATGCCCCGCGCTGTTG	FAM-5'-ATCGGTGCTAGAACCTGGATTTGG- 3'-TAMRA
<i>Nrp1</i>	ACAGCAAGCGCAAGGCTAA	AGGTGAAAACGTCCGAAGCT	FAM-5'-TCGTTCGAAGGCAACAACAACACTATG- 3'-TAMRA